<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE nitf PUBLIC "-//IPTC//NITF DTD 3.0//EN" "nitf-3-0.dtd"><nitf baselang="EN-US"><head><meta content="CITE" name="_lnbillview"/><meta content="00001" name="_lnminrev"/><meta content="May 2, 2017" name="_eoptdate"/><meta content="19:27:35 EDT" name="_eopttime"/><meta content="DOCUMENT_TOKEN_PLACEHOLDER" name="documentToken"/><docdata><doc-id id-string="5NFN-72H1-F0J5-82NR" regsrc="lexisnexis.com"/><date.issue norm="20170701T000000Z"/>2017-07-01</docdata><pubdata unit-of-measure="word" item-length="2934" name=" Belgium Pharmaceuticals &#38; Healthcare Report"/></head><body><body.head><hedline><hl1>Belgium - Q3 2017</hl1></hedline></body.head><body.content/></body></nitf>